LENZ Therapeutics, Inc. (LENZ)
- Previous Close
15.45 - Open
15.33 - Bid 15.37 x 100
- Ask 16.09 x 100
- Day's Range
15.12 - 16.00 - 52 Week Range
2.01 - 24.59 - Volume
200,660 - Avg. Volume
253,649 - Market Cap (intraday)
401.387M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
34.00
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
www.lenz-tx.comRecent News: LENZ
Performance Overview: LENZ
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LENZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LENZ
Valuation Measures
Market Cap
401.39M
Enterprise Value
313.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-5.55
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-77.17%
Return on Equity (ttm)
-157.61%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-69.97M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
65.79M
Total Debt/Equity (mrq)
0.64%
Levered Free Cash Flow (ttm)
-34.21M